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ABSTRACT
Multiple functional challenges in the use of pharmaceutical packaging reveal a great need of packaging
to be designed inclusively. This study investigates patient involvement in the pharmaceutical packaging
design process by analysing interview data from representatives of the pharmaceutical and packaging
industry. Four main themes related to patient involvement were uncovered: patient expertise levels,
patient involvement modes, factors encouraging patient involvement, and factors discouraging patient
involvement. Passive patient involvement modes were found to be dominant due to regulations and a
traditional perspective regarding physical testing. However, active patient involvement modes were
identified, motivated by empathy and understanding of the lives of patients. The pharmaceutical
packaging design process is complex and involves multiple stakeholders. The research findings can
inspire more industry practitioners and policymakers to design pharmaceutical packaging that is
inclusive and with consideration of a broader spectrum of patients’ needs.
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INTRODUCTION
Industrial choices made in design processes
account for the final uses of products (design for
users) and reflect the way the industry itself perceives and involves users in the design process
(design with and by users) [1, 2]. For industries that
are not traditionally user-oriented, it can be particularly challenging to be informed by user inputs
during the design process. The pharmaceutical
industry, associated with the packaging industry, is
an example of an industry that is highly regulated
and centred on science-based drug development [3],
but an industry that has been challenged to deliver
more inclusive and patient-centred alternatives to
treatment and medication intake [4].
Inclusive design means that when designing
products, one should take into consideration users
with different skills and (dis)abilities – which makes
sense when thinking about the different ways people
are affected by a disease and the profound changes
that can come to life during treatment. Regarding
packaging, researchers have stressed the need for
inclusive design in general [5, 6] and pharmaceutical packaging particular [7-13].
Despite its relevance, most of the previous
research has focused on the functional difficulties created by pharmaceutical packaging, without
paying attention to the participation of patients in
the design process [14]. Because of its complex multidisciplinary development, pharmaceutical packaging usually relies on a design process conducted
by what could be called a ‘design collective’ [15].
This means many important design decisions are
often not even made by designers, but by people
from business development, risk management, and
manufacturing who lack training in how to involve
users and address their needs by means of inclusive and user-centred design processes. The same
kind of design collective as well as limitations to
user involvement is expected in pharmaceutical

packaging design, where patient involvement has
been under investigated.
Thus, this study aims to explore current industry
practices of patient involvement when designing
pharmaceutical packaging. The point of departure is that independent of the type of medication,
a pharmaceutical package will only suit patients’
needs if those needs are understood by asking and
letting the patients take part in the design process.
This study considers both prescribed medications (those only sold or given to patients prescribed
by physicians) and over-the-counter medications
(OTCs, medication products that can be marketed
and sold to patients without a physician’s prescriptions). When it comes to packaging, we consider
the primary packaging system level [16], which
includes both the inner packaging (in direct contact
with the medication, such as blisters, plastic bottles,
glass vials) and outer packaging (that contains the
inner packaging, such as a carton board box or
wrapping). We do so because inner and outer packaging are assessed together by regulatory boards
and are viewed as a packaging system that protects
and delivers the medication used by patients.

DESIGNING INCLUSIVE PHARMACEUTICAL
PACKAGING:
FROM
MEDICALISATION TO EMPOWERED
SELF-CARE
Inclusive approaches, such as universal design
[17], inclusive design [18], and design for all [19],
have motivated a new design methodology involving
highlighting who would be able to use the products
of interest and who would be excluded from using
them because of their design [20]. Each of these
inclusive approaches started at a different point
in time and place, but they have a common goal
of integrating the mainstream and subsets of the
population (e.g., people with disabilities and older
people) into the design process. However, inclusive
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design approaches in practice often struggle to
reach their main goals, either because it is demanding to change policies or because there are budget
limitations, time constraints, and an overall lack of
perception of the needs of different users [21].
Inclusive approaches to design call for attention to the level of user involvement. A predominant
and traditional view of user involvement emphasises the ‘expert view’, where an expert is trained to
observe and/or interview a selected group of users
who perform different pre-delimited tasks, test prototypes, or simulate interaction scenarios [22]. As
a result, users are a source of information, with
passive involvement in the design process [23]. Conversely, a participatory approach unites the worlds
of the user and designer and offers more creative and
empathic design process techniques [24]. Currently,
a participatory approach is often referred to as codesign, which means ‘the creativity of designers
and people not trained in design working together in
the design development process’ [22]. By participating and being involved, users are invited not only
to perform pre-defined tasks or test already-made
prototypes in the design process, but also to cocreate and elaborate on concepts via enriched and
hybrid forms of collaboration [25].
The call for user participation in design is not
new [26]. However, it has only been in recent years
that researchers have begun to show a growing
interest in the experiences of patients as users of
products and services that are essential for their care
and directly affect their emotions and well-being
[27, 28]. The increasing focus on patients is linked
to important social and demographic changes, particularly those pertaining to ageing, with people
living longer with chronic conditions and taking
multiple medications every day [29]. The expansion
of medication usage, referred as ‘medicalisation’
[30], draws attention to patients’ in managing their
own care and their agency in taking or not taking
their medication [31].

How patients integrate a treatment into their
lifestyle can determine its success. In that sense,
the pharmaceutical industry constitutes a singular
business case in which an inclusive design approach
is necessary to come up with pharmaceutical packaging that can be used by a broad spectrum of
patients [32]. To motivate the correct intake of medication and adherent behaviour by patients, healthcare agencies and policymakers have called for
innovative solutions that can empower patients and
make them more active in caring for themselves,
especially in the long-term perspective [33]. This
fuels the demand for well-designed medication
products and tools [34].
A way forward to more inclusive pharmaceutical packaging is to involve patients in the design
process. This study looks closer to industry practices in place for patient involvement and to the
level of patient involvement in connection to the different phases of the existing design process.

METHODOLOGY
This research intends to answer two research
questions:
• How are patients involved in the pharmaceutical packaging design process?
• What encourages or discourages patient
involvement in the pharmaceutical packaging
design process?
With these research questions as guidance,
we opted to conduct semi-structured interviews
with professionals who had experienced patient
involvement in the pharmaceutical packaging
design process. This was supported by a qualitative research approach [35], in which qualitative
interviews were performed to gain ‘in-depth information pertaining to participants’ experiences and
viewpoints of a particular topic’ [36]. By doing
that, researchers have the chance to learn from
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accumulated experiences that they could not experience themselves and give the respondents the
opportunity to reflect on their own practices.
Respondent selection
The initial respondents were selected via purposeful sampling [37], based on their past experiences with pharmaceutical packaging design and
their many years of work experience within the
pharmaceutical and/or packaging industry. Additional respondents were added through respondentdriven sampling [38], allowing access to otherwise hard-to-reach respondents within the same or
related organisations. As recommended by the literature, we stopped reaching out to respondents when

response saturation was achieved [39]. The organisations where respondents worked have an international profile, with products attending a range
of markets across the globe, but mostly focused on
the European and North American markets. One
company is based in Asia. Table 1 presents the 25
respondents in the study.
Data collection
An interview script was prepared with openended and discovery-oriented questions, including questions about patient involvement and participation in designing pharmaceutical packaging.
In addition to that, other relevant questions were
added about the holistic process of pharmaceutical

Table 1. Respondent characteristics

Listening to Current Practice: Patient Involvement in the Pharmaceutical Packaging Design Process

Table 1. Respondent characteristics, continued

Data analysis
innovation and the packaging design process.
Over an eight-month-long period, one individual
interview was conducted with each respondent, with
durations ranging from 25 min to 2 h and 17 min, with
an average of 1 h and 14 min. Face-to-face interviews
were preferred, although telephone interviews were
conducted due to geographic constraints in 10 of the
25 cases. Each interview was preceded by obtaining
informed consent, and all of the respondents agreed to
the audio recording of their conversations. Subsequent
follow-ups were conducted via electronic communication and telephone calls for clarification.

All of the audio recordings were transcribed
verbatim. Departing from the original research
questions, we began by adapting the main steps of a
general inductive approach for analysing qualitative
data [40], which consisted in the following phases:
Phase 0 – Preparation of raw data files and export to
qualitative data analysis software (NVivo, QSRInternational); Phase 1 – Close reading of the interview data andinitial themes; Phase 2 – Creation of
a theme scheme; Phase 3 – Refinement of the coded
and uncoded text; Phase 4 – Assessment of trustworthiness. Figure 1 summarises the data analysis
process.

Journal of Applied Packaging Research

5

Figure 1. Data analysis process
Table 2. Final coding scheme
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By successive re-reading of the raw data,
relevant segments of text were classified according
to the initial unstructured themes and subthemes
until four main themes clearly emerged by the
end: patient expertise levels, patient involvement
modes, factors encouraging patient involvement,
and factors discouraging patient involvement. Table
2 presents the final coding scheme.

ANALYSIS OF KEY FINDINGS
In the following sections, we present and
analyse the key findings that emerged from the
interviews. Selected quotations illustrate how the
respondents expressed themselves and synthesise some of the key findings. Minor edits of the

quotations, enclosed in brackets, were made to
facilitate comprehension – for instance, pauses or
broken sentences were removed.
Patient expertise levels
Users have different expertise levels depending
on their previous product usage [41]. We identified
respondents were concerned with the patients’ level
of expertise and patients’ awareness and acceptance
of their own health conditions. Figure 2 illustrates
the three patient expertise levels emerged from the
interview data: pre-patient, experienced patient,
and patient advocate.
Pre-patient
A pre-patient is considered a naïve patient who
has just become aware of the disease or condition.

Figure 2. Patient expertise levels
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In this sense, a pre-patient is also a future user of
the medication. Commonly, pre-patients refuse
or postpone the beginning of treatment [34]. Prepatients often have high stress levels because they
need to learn how to navigate their illnesses. The
respondents perceived that packaging has a specific
role in helping these patients to find guidance and
instruction to carry out their treatment correctly.
Independent of the disease, pre-patients are more
likely to make mistakes or use the packaging in
unexpected ways, which can help packaging teams
uncover unexpected packaging use.
Experienced patient
Experienced patients are those patients who
have lived with one or more diseases for a long
time. They have tacit knowledge, which means they
‘have in mind a pattern born of experience, which
they can overlay on a particular problem and use to
quickly detect a solution’ [48]. Experienced patients
are often of the greatest interest to packaging design
teams, as those patients have extensive experience
living with certain conditions and have developed
their own strategies to cope with both their condition and the functional challenges that they might
face with the medication and its packaging.
Patient advocate
The third level is the patient advocate level. In
the literature, a closely related concept would be the
‘lead user’ [2]. Lead users combine expertise in the
context of usage with the eagerness to innovate and
perform product design changes. However, we could
not identify patients as lead users in our interview
data, as the patients were never mentioned as the
initiators of pharmaceutical packaging innovations.
Therefore, a more appropriate concept is ‘patient
advocate’: a person who assumes the responsibility of advocating and talking about the needs of a
whole group of users, as defined by [49].
Typically, patient advocates are members of

patient associations, a network of patients engaged
in their diseases, treatment, and quality-of-life
improvement. Patient advocates are considered to
be extremely involved in their diseases, which may
demand caution from packaging teams, as not all
patients will be as engaged as these patients.
Patient involvement modes
Arnstein [26] described a taxonomy of user
involvement ranging from non-participation to
tokenism and then citizen power. Similarly, Damodaran [44] defined three user involvement levels:
informative (user provides information and passively helps generate data), consultative (user
comments on pre-defined concepts or prototypes),
and participative (user actively influences decisions). Kaulio [1] proposed another scale in which
the design process is conducted for, with, or by
users. In general, the prevalent idea behind these
similar classifications is that user involvement will
vary from passive to active, depending on when
and how users enter the design process and to what
extent they are allowed to influence it. Inspired by
the literature on user involvement, our iterative
coding process led us to identify and synthesise six
patient involvement modes, presented in Table 3.
Ethnography
Respondents mentioned ethnography as one
mode of patient involvement to discover the ‘world
of the patient’. Hence, ethnography worked as
a sort of inspiration for defining patient needs,
understanding the lives of patients, and identifying ‘exactly how our products will live with the
patients’ (D12). Anthropologists at the company, or
hired by the company, would travel across the globe
to meet patients at their homes to observe the use of
the medication and packaging in real-life situations.
They [the anthropologists] got permission
to follow a patient a whole day to see how
he managed, administrated his medication.
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Table 3. Patient involvement modes and levels
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Where he [the patient] started, how he used
it, and just looking at him, and following him
the whole day. And that gives extremely good
information for us to see where the hurdles
are for him [the patient]. (D5)
The respondents also commented that ethnography is used to add stimuli to the reality of the
patients, especially when testing preliminary packaging design concepts with a group of patients with
one specific disease.
Talks by patients
Respondents commented that they had attended
talks given by patients. These talks were arranged
as very explorative and inspirational seminars at the
companies’ premises, where patients talked with
staff from different departments about the reality of
being a patient and living with a disease.
We invite them here for seminars, we invite
them to talk about their lives, you know. So,
it’s extremely important that we understand
them thoroughly. (D1)
The talks permitted the patients to frame and
phrase their realities, instead of having someone
observe them. D6 commented that patients ‘[...]
come and tell about the experience of having the
disease, and how they perceive the products and the
challenges’. For D5, the meetings with the patients
focused on exploring ‘what is a daily life for you
with this disease?’, rather than asking patients to
assess specific medication or package.
Co-creation workshops
Another means of involving patients early in the
development of new packaging designs is via co-creation workshops, during which the packaging design
team and selected patients interact to develop new
packaging concepts together and iteratively.
We have gone off-site for a couple of days,
and we’ve had different patients in and we

had interview sessions, where essentially I
conducted an interview with a patient for an
hour, and then ten engineers would sit and
listen to the patient, how they live, what theirproblems are, and then go away for an hour,
and come back with three different concepts
to improve their life, just the ideas, an app, a
device, or anything it could be. (D12)
At these sessions, the patients worked with
sketches or very rough mock-ups to visualise future
packaging concepts, not necessarily connected to
one new specific medication but related to a disease
or condition patients had in common.
So, we asked some people to do some
drawings, for example, people said ‘Ok, it
should look like this’. And someone drew
it, ‘Yeah, but you need to be able to put it
in your pocket and in your purse’, you know,
it should be small. So, we started with a
problem, you know, and we tried to see how
they would like to solve that. (D1)
Rapid prototyping and visualisation workshops
A common practice highlighted by the respondents is the presentation of rapid prototypes and
visualisation workshops with patients (Figure 3).
The prototypes were usually developed by in-house
3D printers or by packaging suppliers. As specifically commented by P4, workshops with rapid prototypes permitted designers and engineers to show
patients possible solutions in one or more visual and
tridimensional artefact, which could be helpful to
start an in-depth discussion.
Usability testing
Several respondents commented on their experiences with or awareness of usability tests, performed according to strict documentation and
standard protocols. For pharmaceutical manufacturers, usability testing is an obligatory phase for
certain packages (e.g., child-resistant packages),
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[...] so, we will take all the complaints, work
why patients were complaining about it and
then make some proposed changes to the
pack. And again, just test those within a
small number of people and see what they
say. And hopefully launch a better pack, a
new improved pack. (D10)
Factors encouraging patient involvement

Figure 3. Examples of rapid prototypes tested by
patients. Source: Respondent P3
during which the packaging design is validated.
Regularly, the usability tests were filmed, and
patients were asked to make comments during their
interactions with the packaging.
You put the system in the hand of the patient,
and they have to operate the system. And the
company has to document that the patient is
able to use it. That they don’t do dangerous
mistakes and so on. So that is perhaps the
most important feedback mechanism during
development. (D6)
Formal patient feedback
Formal patient feedback was also mentioned
by the respondents. Any formal feedback about
the packaging reported by patients to the ombudsman service at the pharmaceutical manufacturer
requires the packaging teams’ attention, which has
to analyse and discuss improvements. This situation
is rare according to the respondents and should be
prevented. There is also informal feedback about
the packaging, which is gathered by sales people
or marketing teams. Informal feedback does not
require immediate responses from pharmaceutical manufacturers but serves to provide insights for
future development.

By involving users, designers benefit from
feedback at multiple phases and simultaneously
create solutions that satisfy user needs [47]. In
this research, patient involvement was found to be
important when the packaging is a critical part of
the treatment and a potential hazard causing failure
and severe mistakes. Three subthemes emerged and
are detailed in the following.
Understanding actual usage
Respondents are encouraged to involve patients
to learn and understand the realities of drug product
usage, especially during discovery-oriented stages
of packaging design. Identifying the differences
between the intended and actual usage is one of the
major benefits of patient involvement in the packaging design process for pharmaceutical products:
The user [patient] might think something is
good and it’seasy to use, but if you observe
how they use it, they might use it wrong,
or they might have difficulty using it, even
though they say they think it’s easy. [...] How
they actually use it, not how they think they
use it. (D12)
So actually, we observe to see if they don’t
use it as we intended, so from my point of
view, it’s very important that the designer
that designed this box is observing instead of
reading a report afterwards. (D11)
In another example, a participant told a short
anecdotal story about facing the struggle of a patient
with a package.
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There was a patient here, in a big meeting,
and she was enthusiastic, and she said ‘this
is a fantastic product, it helps me very, very
much’, and she showed the [package] and she
said ‘well, it’s very hard to get it out, because
you have to press out this [name] product out
of the [package], and I have arthritis also in
my hands. I have a trick’. And she said ‘I take
a plastic bag and I put the [package] on that,
and then I press it with my foot, and then I
take it out and use it, and it works fine’, she
said. And it was really embarrassing hearing
this, you know. (D1)
In this situation, the personnel involved with the
medication project at the company had the opportunity to meet the patient to hear about her experience with the medical product. However, it turned
out that the packaging was at the centre of attention. The unexpected method of getting the product
out of the package provided the design team with
insights about the packaging design.
Creating empathy with patients
Eagerness to empathise with patients was mentioned as an encouraging factor. Importantly, some
of the respondents referred to empathy with patients
as part of the organisational culture shared among
the employees at the company level and extending
beyond the packaging team.
I saw a presentation of somebody [...] and
one of his keywords was not designed for
the patient, for the user, but with the user.
He could show he changed the design of an
injectable design packaging for RA [rheumatoid arthritis], with patients’ involvement.
(A2)
Meeting the patients was also an opportunity to
be ‘challenged by somebody who actually has this
everyday use and be surprised by what their perception is compared to your perception of reality’

(D11). By creating empathy with the patients, the
packaging teams could elaborate on future solutions to facilitate medication intake and improve
adherence rates.
Compliance with regulations
Our data show that patient involvement in packaging development is strongly influenced by the
specific policies and regulations, which vary across
different markets. It is the responsibility of pharmaceutical manufacturers to comply with regulations; however, packaging suppliers are also motivated to perform user tests to fulfil the regulations
and queries of their customers (i.e., pharmaceutical
manufacturers). For instance, one important piece
of legislation mentioned is the Poison Prevention
Packaging Act of 1970 (PPPA) for the US market
[50], which requires child-resistant packaging for
several household packages, including prescribed
medication and over-the-counter products.
Factors discouraging patient involvement
We identified three factors that were particularly challenging according to respondents: who
to involve and when to involve them, the available
resources, and what is allowed.
Who to involve and when to involve them
Active and participatory involvement should
start early in the development process. Our data
revealed that it was difficult to define the right point
of patient involvement. For instance, P2 commented
that the company is global, which makes it difficult
to select and work with local patient organisations
in patient recruitment. Another respondent (M2)
commented that interacting with patients in early
phases without having a concept to discuss can be
misguiding and impractical. On the other hand,
bringing ‘something that looks like a final product’
(M2) is also not positive, as time would have passed
in developing something that patients may dislike.
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Additionally, patients living with a certain chronic
condition are not always a homogeneous group,
with a variety in their level of expertise as well.
Available resources
Another discouraging factor includes the operationalisation of patient involvement, such as budget,
time, and extensive documentation. The development of a new medication takes many years and
is a high-cost investment, which means packaging
needs to be seen as a critical element for the medication project. For instance, this happens when a new
medication requires additional protection or packaging features that cannot be supplied by a packaging that has been previously developed. Otherwise,
pharmaceutical manufacturers will more likely use
the packages already in their portfolio to decrease
development costs and increase speed to market.
Moreover, developing inclusive packaging
focused on patients’ needs is embedded in the
culture of some major pharmaceutical manufacturers, but it is not the priority for all companies
involved with the packaging design process, as
stated by one respondent:
Many don’t have the resources, don’t have
the leadership who demands this to happen.
You can have companies very, very active,
pro-active, and others are not, it’s not part of
their genes. (A2)
What is allowed
Most of the activities that involve patients need
to be performed by consultancies or third parties
outside the facilities of a company, which requires
ethical considerations. As commented, ‘pharmaceutical companies, they want to get patients involved
but they have legal restrictions in their communication with patients that makes it difficult’ (A1). For
medications that are planned to be sold globally,
there is an additional complication of dealing with
different regulatory boards and guidelines that

restrict patient involvement for major and global
medication projects where many market opportunities are foreseen.
‘cause it is quite a big investment to run a
usability study, it takes time and it is a little
bit complicated for the industry to interface
and compensate the test participants for their
time, and there is a lot of regulations on that,
so it is important that we get good output for
the pack. (M2)

DISCUSSION
Pharmaceutical packaging can put patients at
risk when different design aspects are not considered [13]. As expected, one main factor encouraging patient involvement is proof that the packaging is safe for use and complies with the relevant
policies and regulations. Therefore, it is imperative to understand the actual use of packaging by
involving patients in situations that mimic their
reality of medication usage. This motivation found
in our results is not distant from what the literature suggests about involving users in design processes to achieve understanding of the context of
use, getting access to first-hand knowledge about
the contexts in which products are used [51].
Luck [52] affirmed that ‘the social process
of participatory design and design dialogue has
enabled the transfer of user knowledge to designers who may be able to use this knowledge for the
users’ benefit’. However, it is not easy to transport
the ideals of inclusive design into practice without
the creation of user stereotypes and common disabilities [53, 54]. We found that stereotypes could
be deconstructed when patients had the opportunity
to share their stories. The talks given by patients
provided an open environment for these patients to
discuss what was important to them. As supported
by previous research [55], patients sometimes
showed creativity and a strong will to circumvent

Journal of Applied Packaging Research

13

difficulties to succeed in their treatment, surprising
the professionals responsible for packaging development.
The discouragement factors for patient involvement identified relate to those already found by the
literature [21]. These factors seemed to be stressed
even more in the pharmaceutical packaging context
as this is a highly regulated business with significant differences across countries, where forceful
regulatory bodies control medication and packaging development to ensure patient safety [56]. Theregulatory differences among borders create a difficult scenario for pharmaceutical companies, as
one new packaging does not fit all the company’s
markets. This can make it particularly difficult to
achieve the ideals of inclusive design, where packaging is intended to be designed for abroader range
of the population but framed by regulations that
impose different demands on the design process,
and directly affect how a final package may look
like. In practice, this means changing a packaging already launched will only be done when absolutely necessary, and not always motivated by the
needs expressed by patients. Packages already
launched tend to remain in the company’s portfolio – and that explains why many pharmaceutical
packaging designs that are functionally challenging to patients continue to be produced for decades
[14]. Conversely, an opportunity arises when a new
medication is under development with a need for
a new packaging – in those cases, having patients
involved in the design process seems to be particularly valuable to the creation of packaging that fits
with patients’ needs.
One interesting aspect was the level of expertise of the patients involved. Scholars have reported
that user participation is often realised with the professionalisation of public participants [57]. This
feature was partly identified in this study, as patients
engaged in patient associations were a recurrent
source of knowledge for the packaging teams.

Experienced patients were repeatedly included,
although patients with little or no experience were
also involved, as different ranges of experience
expanded the understanding of usage. However, it is
important to consider that patients might also lack
a systematic view of all the complexities that are
embedded in pharmaceutical packaging development, from regulatory constraints to intricate supply
chains around the globe. Even though we could
identify many efforts made to involve patients, and
a great interest of the professionals inlistening to
patients’ experiences, limitations on how the pharmaceutical business model is established make it
challenging to have patient involvement that goes
beyond informative and/or consultative roles or to
pursuit packaging that is designed for inclusivity.
Inclusive pharmaceutical packaging remains as an
exception – a view to be challenged by the efforts of
many different actors, from patient associations to
regulatory bodies and other decision-makers.

CONCLUSION
This research has investigated industry practices of patient involvement for inclusive pharmaceutical packaging design. By asking: ‘How are
patients involved in the pharmaceutical packaging
design process?’, we explored the patient involvement modes and levels and the extent to which the
professionals working with packaging design and
patients in fact work together in the design process.
Our findings revealed:
• Six modes of patient involvement were identified (ethnography, talks by patients, co-creation
workshops, rapid prototyping and visualisation
workshops, usability testing, and formal patient
feedback) at different phases of packaging
design process.
• The level of patient involvement was mainly
informative or consultative, where patients
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were asked to give their input on packaging
concepts during development or to share their
experiences of living with a disease or chronic
condition.
• Long-term and in-depth patient involvement
(e.g., ethnography) was limited in comparison
to shorter and punctual mode of patient involvement.
We also asked: ‘What encourages or discourages patient involvement in the pharmaceutical packaging design process?’ The encouraging
factors were:
• Understanding and comparing intended and
actual usage of the medication and its packaging, by adding stimuli to the world of the
patients.
• Creating empathy with patients to better understand their needs and the reality (and complexity) of being a patient.
• Compliance with regulations as a ‘must-do’, as
packaging and medication need to be approved
together at the end.
Conversely, discouraging factors were:
• Difficulty in knowing which patients to involve
and when to involve them in the pharmaceutical
packaging design process.
• Restricted availability of resources (time,
budget for packaging design, human resources)
to conduct studies with patients, combined with
the view of packaging as an additional cost to
the medication project.

having more inclusive pharmaceutical packaging,
because without involving patients or by involving
them only passively, their actual needs cannot be
fully addressed. By affecting the lives of millions
of patients, the pharmaceutical industry can benefit
from a vision of inclusion and participation in its
design processes.
A research agenda can explore other complex
themes related to designing inclusive pharmaceutical packaging in connection with major societal
challenges. We suggest two themes related to this
study that can be further explored:
• The extensive use of medication packaging and
self-care: limited research exists presenting the
routines and strategies followed by patients in
their use of medication packaging in daily life.
Studies in this area can apply different methods
to gain insights about the complexities lived by
patients, such as older patients, in their medication management.
• Methods for implementing gained insights into
industrial design processes and for decisionmaking for inclusive design of pharmaceutical packaging: a path forward is to observe
and research closely how packaging design
teams work to manage and implement insights
from patients in new or improved packaging
concepts, and how decisions are made impacting on the packaging design.

• Long approval process in a highly regulated
industrial context that add complexity to development, reducing the speed to market for the
medication.
Overall, our study has stressed the singularities of designing for patients and with patients.
Patient involvement is one part of the challenges of
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